Synthesis of Oligodeoxynucleotides
165.5; MS m/z calcd for M + H 1001.3883, found 1001.3887.
Anal. Calcd for C40H49N4O9P‚2H2O: C, 56.74; H, 6.31; N, 8.10.
Found: C, 56.95; H, 6.04; N, 7.90.
84.3, 84.5, 84.6, 85.4, 86.9, 87.7, 111.2, 113.1, 116.5, 126.9,
127.7, 129.8, 134.9, 135.0, 135.2, 140.2, 143.8, 143.9, 150.2,
150.3, 158.4, 159.9, 16.37; MS m/z calcd for M + H 1115.4747,
found 1115.4748. Anal. Calcd for C55H75N6O13PSi2: C, 59.33;
H, 6.78; N, 7.53. Found: C, 59.80; H, 7.00; N, 7.30.
Cya n oeth yl 5′-O-(4,4′-Dim eth oxytr ityl)th ym id in e-3′-yl
N-Diisop r op ylp h osp h or a m id a te (5). To a solution of the
thymidine phosphoramidite unit 1 (470 mg, 0.63 mmol) in CH3-
CN (5 mL) was added t-BuOOH (5 M solution in decane, 0.5
mL, 2.5 mmol). After being stirred at room temperature for
10 min, the mixture was diluted with CHCl3. The CHCl3 layer
was washed three times with brine, dried over Na2SO4,
filtered, and evaporated under reduced pressure. The residue
was chromatographed on a column of silica gel (10 g) with
hexane-CHCl3 (50:50-0:100, v/v) containing 1% pyridine and
then with MeOH-CHCl3 (0:100-3:97, v/v) containing 1%
pyridine to give the title compound (468 mg, 80%): 1H NMR
(CDCl3) δ 1.09-1.35 (m, 15H), 2.33-2.72 (m, 4H), 3.34-3.50
(m, 4H), 3.77 (s, 6H), 4.00-4.29 (m, 3H), 5.03 (br s, 1H), 6.43
(dd, 1H, J ) 5.4 Hz, J ) 8.9 Hz), 6.81 (d, 4H, J ) 8.9 Hz),
7.13-7.59 (m, 10H), 8.66 (d, 1H, J ) 8.6 Hz); 31P NMR (CDCl3)
δ 8.03, 8.33; 13C NMR (CDCl3) δ 11.7, 19.6, 39.4, 46.3, 46.4,
63.4, 77.3, 84.3, 84.4, 87.0, 87.1, 111.5, 111.6, 113.1, 113.2,
126.9, 127.1, 127.6, 127.9, 128.1, 128.9, 129.0, 130.0, 134.8,
134.9, 135.0, 135.3, 139.3, 143.8, 143.9, 150.2, 158.4, 158.6,
163.4; MS m/z calcd for M + H 761.3505, found 761.3317. Anal.
Calcd for C40H49N4O9P‚1/2H2O: C, 62.41; H, 6.55; N, 7.27.
Found: C, 62.66; H, 6.62; N, 7.14.
Cya n oeth yl 5′-O-(4,4′-Dim eth oxytr ityl)th ym id in e-3′-yl
P h osp h on a te (6). To a solution of the thymidine phosphora-
midite unit 1 (470 mg, 0.63 mmol) in CH3CN-H2O (9:1, v/v, 3
mL) was added 1-H-tetrazole (88 mg, 1.26 mmol). After being
stirred at room temperature for 10 min, the mixture was
diluted with CHCl3. The CHCl3 layer was washed three times
with brine, dried over Na2SO4, filtered, and evaporated under
reduced pressure. The residue was purified by flash chroma-
tography on silica gel to give the title compound (354 mg,
85%): 1H NMR (CDCl3) δ 1.34 (s, 3H), 2.38-2.70 (m, 4H),
3.30-3.48 (m, 2H), 3.69 (s, 6H), 4.10-4.21 (m, 3H), 5.17 (s,
1H), 6.36 (dd, 1H, J ) 5.4 Hz, J ) 8.1 Hz), 6.76 (d, 4H, J )
8.6 Hz), 6.82 (d, 1H, J ) 725.0 Hz), 7.06-7.45 (m, 10H), 9.77
(d, 1H, J ) 11.3 Hz); 31P NMR (CDCl3) δ 7.57, 7.60; 13C NMR
(CDCl3) δ 11.9, 19.8, 19.9, 20.1, 39.2, 55.4, 60.5, 60.6, 60.7,
63.1, 77.6, 84.3, 87.3, 111.7, 113.3, 116.5, 123.9, 125.3, 127.2,
128.0, 130.1, 135.0, 135.2, 149.2, 150.7, 150.8, 158.7, 164.1;
MS m/z calcd for M + Na 684.2086, found 684.2135. Anal.
Calcd for C34H36N3O9P: C, 61.72; H, 5.72; N, 6.29. Found: C,
61.73; H, 5.78; N, 6.35.
4-N-[5′-O-(4,4′-Dim eth oxytr ityl)th ym id in e-3′-yl](2-cya -
n oeth yl)p h osp h or yl-3′,5′-O-bis(ter t-bu tyld im eth ylsilyl)-
d eoxycytid in e (7). A mixture of the thymidine 3′-O-phos-
phoramidite unit 1 (500 mg, 0.67 mmol) and 3′,5′-O-bis(tert-
butyldimethylsilyl)deoxycytidine 9 (204 mg, 0.449 mmol) was
rendered anhydrous by repeated coevaporation successively
three times each with dry pyridine, dry toluene, and dry CH2-
Cl2 and finally dissolved in dry CH3CN (5 mL). To the solution
was added 1H-tetrazole (70 mg, 0.674 mmol). After the mixture
was stirred at room temperature for 1 h, a 1 M solution of I2
in pyridine-H2O (9:1, v/v, 3 mL) was added to the mixture.
After being stirred at room temperature for 2 min, the mixture
was diluted with CHCl3. The CHCl3 layer was washed three
times with aqueous 5% Na2S2O3, dried over Na2SO4, filtered,
and evaporated under reduced pressure. The residue was
chromatographed on a column of silica gel (10 g) with hexane-
CHCl3 (50:50-0:100, v/v) containing 1% pyridine and then
with MeOH-CHCl3 (0:100-3:97, v/v) containing 1% pyridine
to give the title compound (400 mg, 80%): 1H NMR (CDCl3) δ
0.07 (s, 6H), 0.10 (s, 6H), 0.79 (s, 9H), 0.82 (s, 9H), 1.39 (s,
3H), 2.10-2.81(m, 6H), 3.32-3.58 (m, 2H), 3.78 (s, 6H), 3.82-
4.02 (m, 1H), 4.10-4.38 (m, 5H), 5.10-5.22 (m, 2H), 6.15-
6.34 (m, 3H), 6.76-6.82 (m, 4H), 7.23-7.33 (m, 9H), 7.46 (s,
1H), 7.71 (m, 1H); 31P NMR (CDCl3) δ 5.28, 5.16; 13C NMR
(CDCl3) δ -5.5, -5.4, -4.9, -4.6, 11.6, 17.9, 18.3, 19.5, 19.6,
25.6, 25.8, 39.1, 41.8, 55.2, 60.9, 61.0, 62.1, 63.2, 70.8, 76.9,
2-Cya n oeth yl 5′-O-(4,4′-Dim eth oxytr ityl)th ym id in e-3′-
yl P h osp h a te (8). To a solution of compound 6 (260 mg, 0.39
mmol) in pyridine-H2O (9:1, v/v, 3 mL) was added a 0.1 M
solution of I2 in pyridine-H2O (9:1, v/v, 20 mL). After being
stirred at room temperature for 2 min, the mixture was diluted
with CHCl3. The CHCl3 layer was washed three times with
aqueous 5% Na2S2O3, dried over Na2SO4, filtered, and evapo-
rated under reduced pressure to give 8 (300 mg 99%): 1H NMR
(CDCl3) δ 1.28-1.45 (m, 12H), 2.17-2.67 (m, 4H), 3.04 (dd,
1H, J ) 7.29 Hz, J ) 14.6 Hz), 3.38 (d, 1H, J ) 8.91 Hz), 3.49
(d, 1H, J ) 7.83 Hz), 3.78 (s, 6H), 3.98 (s, 2H), 4.29 (s, 1H),
4.97 (s, 1H), 6.42 (s, 1H), 6.83 (d, 4H, J ) 8.91 Hz), 7.23-7.63
(m, 10H), 8.52 (br s, 1H), 12.23 (br s, 1H); 31P NMR (CDCl3) δ
-1.17; 13C NMR (CDCl3) δ 8.6, 11.6, 19.8, 19.9, 45.6, 55.1, 60.1,
77.3, 84.4, 86.8, 110.9, 112.8, 113.0, 17.7, 125.0, 126.9, 127.7,
128.0, 128.8, 129.9, 135.1, 135.2, 135.3, 135.4, 144.0, 158.4,
163.9. Anal. Calcd for C40H51N4O10P‚1H2O: C, 60.29; H, 6.71;
N, 7.01. Found: C, 60.39; H, 6.97; N, 6.52.
Typ ica l P r oced u r e for Solid -P h a se Syn th esis. Each
cycle of chain elongation consisted of detritylation (3% trichlo-
roacetic acid in CH2Cl2, 2 mL, 1 min), washing [CH2Cl2 (1 mL
× 3), THF (1 mL × 3)], coupling [an appropriate phosphora-
midite unit (20 µmol) in THF (200 µL), NBT (12.5 mg, 40 µmol)
in THF (200 µL), 1 min], and washing (THF (1 mL × 3)),
oxidation (0.1 M I2, pyridine-H2O (9/1, v/v), 2 min), and
washing [pyridine (1 mL × 3), CH3CN (1 mL × 3), CH2Cl2 (1
mL × 3)]. Generally, the average yield per cycle was estimated
to be 97-99% by the DMTr cation assay. After chain elonga-
tion, the DMTr group was removed by treatment with 3%
trichloroacetic acid in CH2Cl2 (2 mL) for 1 min, and the resin
was washed with CH2Cl2 (1 mL × 3) and CH3CN (1 mL × 3).
The oligomer was deprotected and released from the polymer
support by treatment with concentrated aq NH3 (500 µL) for
40 min. The polymer support was removed by filtration and
washed with CH3CN (3 × 1 mL). The filtrate was evaporated
and purified by reversed-phase HPLC or anion-exchange
HPLC.
Th e Sta bility of th e DMTr Gr ou p on P olym er Su p -
p or ts u n d er Acid ic Con d ition s Sim ila r to Th ose Used
for t h e Con d en sa t ion of t h e P r ot on -Block Met h od .
DMTr-ON T10 (1 µmol) on a HCP resin or CPG resin was
synthesized by use of an ABI 392 DNA/RNA synthesizer. The
resin was treated with a THF solution (400 µL) of NBT (12.4
mg, 40 µmol), diisopropylamine (2.8 µL, 20 µmol), and 5′-O-
DMTr-deoxyadenosine (11.0 mg, 20 µmol) for 10 min. The
oligomer was deprotected and released from the polymer
support by treatment with concentrated aq NH3 (500 µL) for
40 min. The polymer support was removed by filtration and
washed with H2O (1 mL × 3). The filtrate was evaporated to
dryness under reduced pressure. The residue was dissolved
in water and analyzed by reversed-phase HPLC.
Th e Sta bility of d [Ap T] on P olym er Su p p or ts u n d er
Acid ic Con d ition s Sim ila r to Th ose Used for Detr ityla -
tion in th e P r oton -Block Meth od . d[ApT] (1 µmol) without
base protection on HCP were synthesized by use of the proton-
block method. The resin was treated with a 0.2 M solution of
NBT in THF (200 µL) or 3% trichloroacetic acid (400 µL). The
dimer was deprotected and released from the polymer support
by treatment with concentrated aq NH3 (500 µL) for 40 min.
The polymer support was removed by filtration and washed
with H2O (3 × 1 mL). The filtrate was evaporated and purified
by anion-exchange HPLC.
Next [ApT] (1 µmol) with an N-benzoyl group on HCP were
synthesized by use of the general procedure. Then the resin
was treated with 3% trichloroacetic acid (400 µL). the dimer
was deprotected and released from the polymer supports by
treatment with concentrated aq NH3 (500 µL) for 40 min. The
J . Org. Chem, Vol. 68, No. 14, 2003 5491